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Introduction: Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor
prescribed as part of first-line highly active antiretroviral therapy (HAART) in South
Africa. Despite administration of fixed doses of EFV, inter-individual variability in plasma
concentrations has been reported. Poor treatment outcomes such as development
of adverse drug reactions or treatment failure have been linked to EFV plasma
concentrations outside the therapeutic range (1–4µg/mL) in some studies. The drug
metabolizing enzyme (DME), CYP2B6, is primarily responsible for EFV metabolism with
minor contributions by CYP1A2, CYP2A6, CYP3A4, CYP3A5, and UGT2B7. DME
coding genes are also regulated by microRNAs through targeting the 3′-untranslated
region. Expanded analysis of 30 single nucleotide polymorphisms (SNPs), including those
in the 3′-UTR, was performed to identify pharmacogenetics determinants of EFV plasma
concentrations in addition to CYP2B6 c.516G>T and c.983T>C SNPs.
Methods: SNPs in CYP1A2, CYP2B6, UGT2B7, and NR1I2 (PXR) were selected for
genotyping among 222 Bantu-speaking South African HIV-infected patients receiving
EFV-containing HAART. This study is a continuation of earlier pharmacogenetics studies
emphasizing the role of genetic variation in the 3′-UTR of genes which products are either
pharmacokinetic or pharmacodynamic targets of EFV.
Results: Despite evaluating thirty SNPs, CYP2B6 c.516G>T and c.983T>C SNPs
remain the most prominent predictors of EFV plasma concentration.
Conclusion: We have shown that CYP2B6 c.516G>T and c.983T>C SNPs are the
most important predictors of EFV plasma concentration after taking into account all other
SNPs, including genetic variation in the 3′-UTR, and variables affecting EFV metabolism.
Keywords: 3′-UTR, efavirenz, HIV/AIDS, pharmacogenetics, sensitivity, single nucleotide polymorphism,
specificity, South Africa
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INTRODUCTION
Efavirenz (EFV) is a non-nucleoside reverse transcriptase
inhibitor (NNRTI) used as part of highly active antiretroviral
therapy (HAART) in the treatment of human immunodeficiency
virus/acquired immune deficiency syndrome (HIV/AIDS).
Approximately 70% of the 2.5 million HIV-infected South
Africans on HAART as part of first-line antiretroviral
therapy (ART) is now given EFV once-daily (600 mg) in
the following combination; tenofovir disoproxil fumarate
(TDF) + emtricitabine (FTC) or lamivudine (3TC) + EFV
(UNAIDS, 2013). EFV has a half-life of 40–55 h and is preferred
because of its effective virologic suppression (Raffi et al.,
2014). Multiple large randomized controlled trials and cohort
studies have shown potent EFV-related viral suppression with
many patients having viral RNA levels < 50 copies/mL for
up to 6 years of follow-up (Gulick et al., 2006; Cassetti et al.,
2007).
Despite its efficacy and virologic potency, EFV exposure
has been linked to development of serious central nervous
system (CNS) side effects in 20–74% of patients (Fumaz et al.,
2002; Hawkins et al., 2005; Abah et al., 2015). The side
effects include dizziness, headaches, depression, nightmares, and
insomnia (Adkins and Noble, 1998; Marzolini et al., 2001).
Abah et al. (2015) reported an incidence rate of 40.5 adverse
drug reactions (ADRs) per 1000 person-years on EFV-based
treatment among Nigerian HIV/AIDS patients, while up to 74%
of HIV/AIDS patients from Uganda reportedly experienced at
least one EFV-related neuropsychiatric symptomwithin 12 weeks
of therapy (Mukonzo et al., 2013). Nearly 43% of Zimbabwean
HIV/AIDS patients reported CNS toxicity after initiation of
EFV-containing HAART (Dhoro et al., 2015). EFV associated
symptoms range from mild to moderate in severity and subside
progressively within a month after treatment initiation (Moyle,
1999a,b). The severity or persistence of adverse effects can
result in EFV discontinuation and has been reported in about
4–50% of patients (Marzolini et al., 2001; Ward and Curtin,
2006; Kenedi and Goforth, 2011; Leutscher et al., 2013). EFV
concentrations in plasma have been shown to be predictive of
treatment outcomes in certain studies, with low concentrations
potentially resulting in treatment failure, while CNS toxicity
being observed three-times more frequent among patients
with high EFV plasma concentrations (Marzolini et al., 2001;
Kenedi and Goforth, 2011; Leutscher et al., 2013). Achieving
the correct EFV dosage and plasma concentrations within the
suggested therapeutic range of 1–4µg/mL is, thus, crucial. This
observation led to research focusing on identifying genetic
causes of slow or fast EFV metabolism and risk factors of CNS
toxicity.
EFV is metabolized to 8-hydroxy-EFV (major metabolite)
primarily by cytochrome P450 (CYP) 2B6 and to a minor extent
by CYP3A. 7-hydroxy-EFV and N-glucuronide-EFV metabolites
are formed by CYP2A6 and UDP glucoronosyltransferases
(UGT) 2B7, respectively (Ward et al., 2003; Arab-Alameddine
et al., 2009; di Iulio et al., 2009). The formation rate
of both 8-hydroxy-EFV and N-glucuronide-EFV is variable
between human microsomal samples and points to the
involvement of genetic variation in genes coding for drug
metabolizing enzymes (DMEs) (Ogburn et al., 2010; Bae et al.,
2011).
CYP2B6 genetic variants, specifically rs3745274 (c.516G>T)
and rs28399499 (c.983T>C), have been investigated in relation
to EFV pharmacokinetics. Numerous studies have reported an
association between the CYP2B6 c.516T-allele and increased EFV
plasma concentrations, reduced clearance, or increased drug
exposure (Wyen et al., 2008; Holzinger et al., 2012; Cortes et al.,
2013; Swart et al., 2013; Sinxadi et al., 2015). Patients with the
CYP2B6 c.516G/T and c.516T/T genotypes are reported to be
at risk of EFV plasma concentrations associated with toxicity
(Lee et al., 2014). Several recent studies performed in Africa
have reported a CYP2B6 c.516T-allele frequency ranging from
0.20 to 0.49 (Haas et al., 2004; Klein et al., 2005; Mehlotra
et al., 2006; Penzak et al., 2007; Gross et al., 2008; Nyakutira
et al., 2008; Mukonzo et al., 2009; Parathyras et al., 2009;
Ciccacci et al., 2010; Gounden et al., 2010; Jamshidi et al., 2010;
Ikediobi et al., 2011; Brown et al., 2012; Li et al., 2012; Maimbo
et al., 2012; Swart et al., 2012b; Ngaimisi et al., 2013; Sarfo
et al., 2014; Colic et al., 2015). These studies also reported an
association of the CYP2B6 c.516T-allele with high EFV plasma
concentrations (Mukonzo et al., 2014; Naidoo et al., 2014;
Sarfo et al., 2014; Bisaso et al., 2015; Colic et al., 2015; Dhoro
et al., 2015; Dickinson et al., 2015; Sinxadi et al., 2015). Thus,
CYP2B6 c.516G>T genotyping has been suggested to identify
poor metabolizers as part of precision medicine (Haas, 2005;
Haas et al., 2005; Nolan et al., 2006; Cabrera et al., 2009; Swart
et al., 2013). Another CYP2B6 allele, CYP2B6 c.983C is also a
predictor of deficient CYP2B6 activity associated with increased
EFV plasma concentrations in certain populations (Wyen et al.,
2008; Holzinger et al., 2012; Sarfo et al., 2013; Swart et al.,
2013).
Focus on the pharmacogenetics of EFV has mostly been
on genetic variation in CYP2B6 with recent studies also
investigating the role of other genetic variants in CYP1A2,
CYP2A6, CYP3A4, CYP3A5, UGT2B7, ATP binding cassette
subfamily B member 1 (ABCB1) and nuclear receptors pregnane
X receptor (PXR, NR1I2) and constitutive androstane receptor
(CAR, NR1I3) in EFV metabolism (Mukonzo et al., 2009;
Burhenne et al., 2010; Elens et al., 2010; Wyen et al., 2011;
Swart et al., 2012a,c; Cortes et al., 2013; Sarfo et al., 2013;
Sukasem et al., 2014; Haas et al., 2014a,b). The weakness with
most of the studies has been characterization of each gene in
isolation, making it difficult to evaluate the contribution of
each variant together with other variants that cause deficient
activity. Thus, in this study we assessed the effects of other
variants, including 3′-untranslated region (UTR) variation in
genes coding for DMEs involved in EFV metabolism, on EFV
plasma concentration. Previous studies trying to account for
the genetic contribution to inter-individual differences in EFV
plasma concentration were only able to explain a portion of
the observed variability (Holzinger et al., 2012; Swart et al.,
2013). The aim of the current study was to investigate the
role of genetic variation in CYP1A2, CYP2B6, UGT2B7, and
NR1I2 especially polymorphisms within the 3′-UTR on EFV
metabolism.
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METHODS
Study Participants
Bantu-speaking South African HIV/AIDS patients (n = 301)
were recruited from Themba Lethu Clinic, Gauteng, South
Africa and were receiving EFV-based treatment for at
least 6 months. The participants were unrelated adults
as explained previously in Swart et al. (2013). A whole
blood sample (5mL) was obtained from each subject and
used for plasma preparation (14–18 h after EFV dose) and
DNA extraction as described previously by Swart et al.
(2013). Ethical and study approval (HREC REF 103/2009
and M080124) was provided by the University of Cape
Town Health Sciences Faculty Human Research Ethics
Committee, Cape Town, South Africa, and the University
of Witwatersrand Human Research Ethics Committee,
Gauteng, South Africa. Written informed consent was
obtained from all participants and this study was performed
in accordance with guidelines of the Helsinki Declaration
of 2008.
Selection of Single Nucleotide
Polymorphisms (SNPs) and Genotyping
Methods Used
Earlier studies have mostly investigated the role of exonic and
promoter single nucleotide polymorphisms (SNPs) in CYP1A2,
CYP2A6, CYP2B6, and CYP3A on EFV plasma concentration
(Wyen et al., 2008; Holzinger et al., 2012; Swart et al., 2012a,c,
2013; Cortes et al., 2013; Sarfo et al., 2013; Evans et al., 2015;
Sinxadi et al., 2015). This study is a continuation emphasizing
the role of genetic variation in the 3′-UTR of genes which
products are either pharmacokinetic or pharmacodynamic
targets of EFV. Thus, additional SNPs in CYP1A2 [EMBL:
ENSG00000140505; Genbank: NC_000015.10, NM_000761],
CYP2B6 [EMBL: ENSG00000197408; Genbank: NC_000019.10,
NM_000767], UGT2B7 [EMBL: ENSG00000171234; Genbank:
NC_000004.12, NM_001074], and NR1I2 [ENSG000000144852;
Genbank: NC_000003.12, NM_022002] were selected for
genotyping. The SNPs were selected for investigation based on
functional significance. SNPs were genotyped using polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP), SNaPshot mini-sequencing or cycle sequencing.
PCR-RFLP genotyping and SNaPshot mini-sequencing methods
were designed and PCR amplification conditions, digestion
patterns and internal SNaPshot primer sequences are shown in
Supplementary Table S1.
PCR amplification for the 3′-UTR of CYP1A2, CYP2B6,
and NR1I2 was performed as described by Swart and Dandara
(2014). PCR amplification was followed by digestion using
the appropriate restriction endonuclease (Supplementary
Table S1) when PCR-RFLP genotyping was used. Direct cycle
sequencing of the 3′-end of NR1I2 3′-UTR with the reverse
primer (Supplementary Table S1) was also used for further
genotyping. The CYP1A2 (c.9-154C>A), CYP2A6 (c.1093G>A),
CYP2B6 (c.136A>G, c.485-18C>T, c.516G>T, c.785A>G,
c.983T>C), CYP3A4 (c.-392G>A), CYP3A5 (c.219-237G>A,
c.624G>A, c.1035_1036insT, c.14T>C), ABCB1 (c.1236T>C,
c.193A>G,c.3435T>C, c.2677G>T/A), NR1I2 (c.448+72G>T,
c.96-7659C>T, c.912-93G>A), and NR1I3 (c.540C>T, c.239-
1089T>C, c.239-99C>T) SNPs were genotyped using either
PCR-RFLP or SNaPshot mini-sequencing as described previously
by Swart et al. (2012a), Swart et al. (2012b), Swart et al. (2012c),
Swart et al. (2013), and Evans et al. (2015).
PCR amplification of UGT2B7 was performed using the
following conditions: 3min at 94◦C; 40 cycles of 94◦C for 30 s,
an annealing temperature of 58◦C (PCR fragment including
UGT2B7 c.-161T>C, c.372A>G, c.211G>T, and c.673G>A)
or 60◦C (PCR fragment including UGT2B7 c.733A>G and
c.802T>C) for 30 s, 72◦C for 2min; and 10min at 72◦C for
final extension (Supplementary Table S1). PCR reactions were
carried out using a “T100 Thermal cycler” from Bio-Rad (Bio-
Rad Laboratories, Hercules, CA, USA). Each PCR reaction
contained the following reagents; 50–100 ng of genomic DNA,
1 X Green GoTaq Reaction Buffer (Promega Corporation,
Madison, WI, USA), 0.2mM of each of the deoxynucleotide
triphosphates (dNTPs) (Bioline, London, UK); 1.5mM MgCl2
(Promega Corporation, Madison, WI, USA); 40 pmol of the
forward and reverse primers (Integrated DNA Technologies,
Inc., Coralville, IA, USA); and 1 U of GoTaq DNA Polymerase
(Promega Corporation, Madison, WI, USA).
For SNaPshot genotyping of four UGT2B7 SNPs, 5µL
of each PCR product was pooled and cleaned-up using 1
U FastAP and 2 U ExonucleaseI (Fermentas Life Sciences,
Burlington, Canada). The FastAP and ExonucleaseI reaction
was incubated at 37◦C for 1 h followed by inactivation
of the enzymes at 75◦C for 15min. SNaPshot single base
extension was performed on the “GeneAmp R© PCR System
2700” (Applied Biosystems, Carlsbad, CA, USA) using the
following conditions; 96◦C for 10 s, 50◦C for 5 s and 60◦C for
30 s for 25 cycles. One microliter SNaPshot™ Multiplex Mix
(Applied Biosystems, California, USA) and the pooled internal
SNaPshot primers (Supplementary Table S1) were used in the
SNaPshot reaction (10µL) (Integrated DNA Technologies, Inc.,
Coralville, IA, USA). The clean-up reaction was repeated using
cycling conditions as mentioned before. An ABI 3130xl Genetic
Analyzer (Applied Biosystems, Carlsbad, CA, USA) was used for
capillary electrophoresis and GeneMapper© Software version 4.1
(Applied Biosystems, Carlsbad, CA, USA) was used to analyse
results.
Statistical Analysis
SHEsis statistical program (Shi and He, 2005; Li et al., 2009) was
used for linkage disequilibrium (D’ and r2) analysis. Statistical
analyses were performed using Graphpad Prism (Version 5,
GraphPad Software Inc., San Diego, CA) and STATA (Version 11,
StatSoft, USA) statistical programs. Mann Whitney or Kruskal-
Wallis (with Dunn’s Multiple Comparison) tests were used to
assess association between clinical parameters, genotypes for
each SNP or haplotypes and median EFV plasma concentration.
EFV plasma concentrations were allocated to each of the
observed haplotypes (i.e., in the event of homozygosity, the
value was counted as two observations). Multivariate logistic
regression analysis was performed to identify predictors of EFV
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plasma concentration by including covariates from the univariate
analysis with a p ≤ 0.15, followed by stepwise backward removal.
Statistical significance for the univariate analysis was defined as
p < 0.05/N (N = number of SNPs or haplotypes in the analysis),
while significance for the multivariate analysis was defined as
p < 0.05/N (N = number of covariates in the analysis) to correct
for multiple testing. Sensitivity, specificity, positive, and negative
predictive values were calculated to determine the predictive
value of each SNP in predicting EFV plasma concentration above
4µg/mL.
Variant allele frequencies in the South African population
group were compared to frequencies in other world populations
obtained from literature. The populations included; Luhya in
Webuye (Kenya), Yoruba in Ibadan (Nigeria), Utah residents
with Northern, andWestern European ancestry, Finnish, British,
and Scottish, Iberians (Spain), Toscani (Italy), Han Chinese,
Southern Han Chinese, Japanese, Colombians, Mexican ancestry
from Los Angeles USA, Puerto Ricans, and Americans of African
ancestry in SW USA (1000 Genomes Project and International
HapMap Project). Pearson’s χ2-test or Fisher’s exact test were
used to compare the allele frequencies of the South Africans to
previously published frequencies in other populations.
RESULTS
Basic Characteristics
The majority (75%) of participants were women of median
age 40 years (range: 22–75 years). Only 7% of the patients
smoked tobacco and 10% consumed alcohol. EFV plasma
concentrations were available for 74% (n = 222/301) of the
patients. Information on clinical parameters including; disease
stage, BMI, CD-4 cell count and viral load were available
from hospital records and were reported previously by Swart
et al. (2012a), Swart et al. (2012c), and Swart et al. (2013).
Adherence to ARV therapy was self-reported and four patients
reported missing a day of treatment. Non-ARV medication co-
administrated with EFV included vitamin B and rifampicin
and 38% (n = 113) of HIV/AIDS patients were treated for
opportunistic infections.
Genotype Frequencies and Linkage
Disequilibrium Analysis
UGT2B7 c.211G>T, c.673G>A, and c.733A>G SNPs which have
been reported in other populations (Guillemette, 2003; Zhang
et al., 2008; Tian et al., 2012; Kim et al., 2014), weremonomorphic
in this South African group. Genotype frequencies for SNPs in
the South African HIV/AIDS patients are shown in Table 1.
Hardy-Weinberg equilibrium (HWE) was calculated for each
SNP and only the genotype frequencies of theUGT2B7 c.372A>G
SNP deviated. Linkage disequilibrium (LD) analysis was
performed for all SNPs in CYP1A2, CYP2A6, CYP2B6, CYP3A4,
CYP3A5, UGT2B7, ABCB1, NR1I2, and NR1I3 (including SNPs
genotyped previously, Swart et al., 2012a,c, 2013; Swart and
Dandara, 2014; Evans et al., 2015). D′ and r2 (correlation
coefficient preferred by the HapMap project) are both measures
of linkage disequilibrium, however, these coefficients are not
independent of allelic frequencies. Figures 1A–D show LD plots
with D′ or r2 for SNP pairs in CYP1A2, CYP2B6, UGT2B7, and
NR1I2. Similar to previously reported findings (Mehlotra et al.,
2007; Swart et al., 2013; Haas et al., 2014a), the r2 LD coefficient
was low for CYP2B6 c.516G>T-c.983T>C SNP pair (r2 = 0.034),
whereas D′ was 0.901.
Correlation of Efavirenz Plasma
Concentration with Genetic Variation and
Clinical Parameters
The median EFV plasma concentration was 2.6µg/mL (range:
0.04–34.4µg/mL). A large degree of inter-individual variability
(860-fold) was observed which has implications for ART
response. Three percent (n = 7) of patients had EFV
plasma concentrations below therapeutic range (1–4µg/mL),
while 31% (n = 69) of patients presented with EFV plasma
concentrations above 4µg/mL. Gender, age, smoking, body
mass index (BMI) at baseline, disease stage, and concurrent
treatment of tuberculosis (TB) did not have a significant
effect on median EFV plasma concentrations, while a trend
towards low EFV plasma concentration was observed for alcohol
consumption (p = 0.015; Table 1). The genotypes of each
SNP were correlated with EFV plasma concentration and data
is presented for SNPs which were successfully genotyped in at
least 75% of participants. As expected, high median EFV plasma
concentrations were observed among carriers of the following
genotypes: CYP2B6 c.516T/T (7.49µg/mL), CYP2B6 c.785G/G
(7.70µg/mL), and CYP2B6 c.983C/C (21.80µg/mL; Table 1). A
trend towards low EFV plasma concentrations for CYP2B6 c.485-
18C/T and T/T genotype carriers (p = 0.0045) and CYP2B6
c.1421T/C and C/C genotype carriers (p = 0.0065) was observed
(Table 1).
Haplotypes were inferred for each patient by including
SNPs with a variant allele frequency greater than 0.1 for
CYP1A2, CYP2B6, and NR1I2 (Supplementary Table S2). No
significant differences in median EFV plasma concentrations
were observed among haplotypes in CYP1A2, UGT2B7, and
NR1I2 (Supplementary Table S2).
Comparison of median EFV plasma concentrations for
CYP2B6 haplotypes (c.136A>G-c.516G>T-c.785A>G-c.
284C>T-c.571T>C-c.799C>T-c.1072G>T-c.1277A>T-c.1355A>
G-c.1399_1400delAGinsCA-c.1421T>C) showed significantly
higher EFV plasma concentrations for the CYP2B6 A-T-G-T-(C
or T)-C-G-(T or A)-G-AG-T haplotype compared to theA-G-A-T-
C-C-G-A-G-AG-T (p < 0.0001) and A-G-A-T-C-C-G-A-G-CA-C
(p < 0.0001) haplotypes (Supplementary Table S2). The CYP2B6
A-T-G-T-C-C-(G or T)-A-G-CA-C, A-T-G-T-C-C-G-A-A-AG-(T
or C) and G-T-G-C-C-C-G-T-G-AG-T haplotypes presented with
EFV plasma concentrations above the recommended therapeutic
range (8.55, 5.98, and 9.29µg/mL). What is common in these
haplotypes, is the CYP2B6 c.516T-allele further demonstrating
its effect on CYP2B6 activity and, therefore, EFV plasma
concentration.
Multivariate logistic regression analysis was performed to
determine variables predictive of EFV plasma concentration
by evaluating the effect of covariates (Table 2). Variables were
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TABLE 1 | Association of basic characteristics, clinical parameters, and genetic variation in CYP1A2, CYP2A6, CYP2B6, CYP3A4, CYP3A5, UGT2B7,
ABCB1, NR1I2, and NR1I3 with median efavirenz plasma concentration.
Basic characteristics or clinical parameters N Median EFV conc. (µg/mL) P-value
222 2.56 (0.04-34.40)
Gender Male 54 (0.25) 2.445 0.9288
Female 167 (0.75) 2.590
Age 218 2.575 0.6040
Smoking Yes 17 (0.08) 1.880 0.2877
No 201 (0.92) 2.590
Alcohol consumption Yes 24 (0.11) 1.865 0.0150
No 194 (0.89) 2.640
BMI at baseline 192 2.615 0.0886
Disease stage 1 128 (0.59) 2.555 0.2217
2 5 (0.02) 1.640
3 66 (0.31) 2.670
4 17 (0.08) 2.990
Concurrent treatment of tuberculosis Yes 14 (0.13) 3.480 0.3361
No 90 (0.87) 2.505
Gene SNP ID SNP Genotype Genotype frequency
position N (freq)
CYP1A2 rs762551* c.9-154C>A C/C 35 (0.12) 26 3.180 0.2734
C/A 151 (0.53) 114 2.640
A/A 101 (0.35) 76 2.270
rs45564134 c.974delG G/G 202 (0.77) 150 2.505 0.8789
G/- and -/- 62 (0.23) 50 2.735
CYP2A6 rs28399454* c.1093G>A G/G 253 (0.86) 190 2.615 0.1920
G/A and A/A 40 (0.14) 32 2.175
CYP2B6 rs35303484* c.136A>G A/A 248 (0.84) 187 2.540 0.7802
A/G 33 (0.11) 27 2.660
G/G 14 (0.05) 8 3.095
rs4803419* c.485-18C>T C/C 247 (0.89) 188 2.640 0.0045
C/T and T/T 30 (0.11) 23 1.840
rs3745274* c.516G>T G/G 107 (0.36) 79 1.970 <0.0001
G/T 133 (0.45) 100 2.510
T/T 55 (0.19) 43 7.490
rs2279343* c.785A>G A/A 110 (0.38) 81 1.940 <0.0001
A/G 132 (0.45) 100 2.510
G/G 51 (0.17) 40 7.695
rs28399499* c.983T>C T/T 253 (0.87) 192 2.395 <0.0001
T/C 32 (0.11) 21 3.620
C/C 5 (0.02) 5 21.80
rs707265 c.1355A>G A/A 15 (0.05) 14 2.590 0.7919
A/G 75 (0.29) 54 2.630
G/G 172 (0.66) 130 2.520
(Continued)
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TABLE 1 | Continued
Gene SNP ID SNP Genotype Genotype frequency
position N (freq)
rs1042389 c.1421T>C T/T 174 (0.63) 133 2.970 0.0065
T/C 90 (0.32) 64 2.190
C/C 15 (0.05) 10 2.270
CYP3A4 rs2740574* c.-392G>A G/G 146 (0.51) 109 2.560 0.8630
G/A 121 (0.42) 91 2.550
A/A 21 (0.08) 16 2.570
CYP3A5 rs776746* c.219-237G>A G/G 7 (0.02) 5 7.020 0.1855
G/A 77 (0.26) 58 2.805
A/A 211 (0.72) 159 2.400
rs10264272* c.624G>A G/G 195 (0.67) 148 2.590 0.5989
G/A and A/A 96 (0.33) 72 2.515
rs41303343* c.1035_1036insT –/– 282 (0.96) 215 2.550 0.6810
–/T and T/T 12 (0.04) 6 2.590
rs15524* c.14T>C T/T 37 (0.13) 29 2.770 0.2638
T/C 114 (0.39) 90 2.670
C/C 144 (0.49) 103 2.280
UGT2B7 rs7668258 c.-161T>C T/T 15 (0.07) 14 2.775 0.2885
T/C 75 (0.34) 58 2.385
C/C 133 (0.60) 96 2.595
ABCB1 rs1128503* c.1236T>C T/C and T/T 60 (0.21) 42 2.730 0.1504
C/C 235 (0.79) 180 2.470
rs2032582* c.2677G>T/A G/G 283 (0.96) 215 2.560 0.3387
G/A and G/T 10 (0.04) 7 2.470
rs1045642* c.3435T>C T/C and T/T 62 (0.21) 43 2.470 0.6126
C/C 233 (0.79) 179 2.560
rs3842* c.193A>G A/A 189 (0.64) 140 2.670 0.1378
A/G 96 (0.33) 75 2.220
G/G 10 (0.03) 7 3.160
NR1I2 (PXR) rs2472677* c.96-7659C>T C/C 97 (0.36) 68 2.660 0.8439
C/T 133 (0.50) 102 2.555
T/T 36 (0.14) 28 2.445
rs3732356* c.448+72G>T G/G 10 (0.03) 6 4.710 0.7447
G/T 123 (0.42) 99 2.680
T/T 162 (0.55) 117 2.390
rs6785049* c.912-93G>A G/G 264 (0.95) 199 2.560 0.9249
G/A and A/A 14 (0.05) 11 2.480
rs3732360 c.522C>T C/C 123 (0.45) 93 2.590 0.1552
C/T 115 (0.42) 87 2.600
T/T 36 (0.13) 23 2.130
rs1054190 c.659C>T C/C 195 (0.90) 152 2.545 0.9843
C/T and T/T 22 (0.10) 19 2.600
rs1054191 c.838G>A G/G 195 (0.72) 152 2.655 0.1553
G/A and A/A 77 (0.28) 55 2.380
rs3814057 c.1195A>C A/A 43 (0.22) 43 2.480 0.3185
A/C 108 (0.54) 108 2.630
C/C 49 (0.24) 49 2.340
(Continued)
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TABLE 1 | Continued
Gene SNP ID SNP Genotype Genotype frequency
position N (freq)
NR1I3 (CAR) rs2307424* c.540C>T C/C 270 (0.91) 208 2.575 0.6195
C/T 25 (0.09) 14 2.510
rs2502815* c.239-99C>T C/C 180 (0.61) 144 2.505 0.2412
C/T 100 (0.34) 65 2.770
T/T 15 (0.05) 13 2.140
rs3003596* c.239-1089T>C T/T 53 (0.18) 39 2.150 0.1365
T/C 140 (0.48) 104 2.515
C/C 100 (0.34) 78 2.805
P < 0.001 were considered significant and are shown in bold. *Genotype-phenotype associations were previously reported by Swart et al. (2012a), Swart et al. (2012c), Swart et al.
(2013), and Evans et al. (2015).
prioritized for inclusion in the multivariate analysis based
on having p < 0.15 in the univariate analysis. Stepwise
removal of variables was performed to assess the effect of
each covariate. Multivariate logistic regression analysis showed
that CYP2B6 c.516G>T and c.983T>C SNPs were the two
most significant predictors of EFV plasma concentration above
4µg/mL (after correction for multiple testing with p < 0.006).
The NR1I2 c.239-1089T>C SNP played a minor role (p =
0.011) in explaining variability in EFV plasma concentrations
(Table 2).
Expanding our investigation to find genetic variants that
are important in predicting EFV plasma concentration, was
motivated by the need to come up with a test for EFV dosing.
Thus, sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) were calculated for individual
SNP genotypes and combinations, considering SNPs included
in multivariate logistic regression analysis. Genotypes and their
combinations were used to predict EFV plasma concentrations
above 4µg/mL (Table 3 and Supplementary Table S3). Seventy-
seven percent (n = 33/43) of patients with the CYP2B6 c.516T/T
genotype had EFV plasma concentrations above 4µg/mL
(Supplementary Table S3). Thus, the CYP2B6 c.516T/T genotype
was associated with the following parameters; sensitivity of 48%
and specificity of 94% in predicting EFV plasma concentrations
> 4µg/mL. Sensitivity of the CYP2B6 c.983C/C genotype (7%)
in predicting EFV plasma concentrations > 4µg/mL was low,
but the specificity (100%) was high. Sensitivity and NPV of the
CYP2B6 c.485-18C/C and c.1421T/T genotypes were high, but the
specificity and PPV were low. Using the CYP2B6 c.516G>T and
c.983T>C SNPs to come up with the CYP2B6 poor metabolizer
phenotype (CYP2B6 c.516T/T or CYP2B6 c.983C/C or CYP2B6
c.516G/T+CYP2B6 c.983T/C) showed the best predictive model
with 68% sensitivity, 93% specificity, 83% PPV, and 87% NPV,
respectively (Table 3).
Comparison of Allele Frequencies Between
Populations
Allele frequencies of SNPs for other world ethnic groups
were obtained from the National Centre for Biotechnology
Information (NCBI) dbSNP database (http://www.ncbi.nlm.nih.
gov/) and the 1000 Genomes Project (http://www.1000genomes.
org/). Statistically significant differences were clearly observed
when the South African groupwas compared to American, Asian,
and European groups. In addition, differences were also observed
when the South African group was compared to the Yoruba
and Luhya (Table 4). For example, NR1I2 c.659T-allele was
present at a frequency of 0.05 in the South African group, absent
among Asians, yet comparable to that of the Americans (0.07–
0.13). In contrast, the UGT2B7 c.211T-allele was absent among
South Africans, other Africans, and Europeans, but present
among Asians (0.11–0.14). Comparison of the NR1I2 c.758G-
allele showed a significantly higher frequency among the Yoruba
(0.19), the Luhya (0.10), and African Americans (0.11) compared
to a frequency of 0.06 among South Africans.
DISCUSSION
Implications for Biomarker Identification,
Disease Diagnosis, or Drug Treatment
This study has taken investigation into pharmacogenetics
determinants of EFV plasma concentration further by evaluating
the contribution of 30 SNPs, especially those in the 3′-UTR
of genes that code for DMEs metabolizing EFV. Most studies
have concentrated on the role of CYP2B6 c.516G>T and
c.983T>C SNPs in predicting EFV plasma concentration. We
report on large inter-individual variability in EFV plasma
concentration supporting previous studies among South Africans
(Gounden et al., 2010) and Swiss patients (Marzolini et al.,
2001; Colombo et al., 2006). Thirty-four percent of the
patients presented with EFV plasma concentrations outside the
therapeutic range (3% below and 31% above) and are at risk
of failing therapy or presenting with ADRs, respectively. This
is similar to observations by Marzolini et al. (2001), Ståhle
et al. (2004), Lubomirov et al. (2011), Mukonzo et al. (2013),
and Sanchez Martin et al. (2013). Poor virologic suppression
and ADRs lead to patient’s health deteriorating which could
lead to increased non-adherence to treatment (ter Heine et al.,
2008).
Drug response is a complex phenotype and multiple factors
including ethnicity, sex, age, body weight, drug-drug, and drug-
food interactions, hepatic impairment, disease state, pregnancy,
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FIGURE 1 | Linkage disequilibrium analysis. (A) CYP1A2, (B) CYP2B6, (C) UGT2B7, and (D) NR1I2. For each, the left figure represents D′-values while the right
figure represents r2-values, respectively.
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TABLE 2 | Multivariate logistic regression analysis of efavirenz plasma concentrations above or below 4µg/mL.
Independent variables Regression coefficient 95% Confidence interval P-value* Change in log likelihood Change in pseudo R2 (%)
CYP2B6 c.516G>T 2.65 (1.75 to 3.55) <0.0001 39.66 29.14
CYP2B6 c.983T>C 2.97 (1.67 to 4.23) <0.0001 20.76 14.36
CYP2B6 c.485-18C>T 0.03 (−1.70 to 1.77) 0.970 1.08 0.07
CYP2B6 c.1421T>C −0.65 (−1.51 to 0.22) 0.142 7.35 2.06
Alcohol consumption −1.13 (−2.49 to 0.22) 0.101 1.22 0.22
BMI −0.04 (−0.13 to 0.06) 0.444 11.71 4.07
NR1I3 c.239-1089T>C 0.89 (0.21 to 1.57) 0.011 2.44 1.62
ABCB1 c.193A>G −0.86 (−1.66 to −0.07) 0.034 1.26 0.98
Variables were included in the multivariate logistic regression analysis based on having a p ≤ 0.15 in the univariate analysis.
*P-values shown are for each variable included in the multivariate logistic regression analysis (log likelihood of -65.24 and pseudo R2 of 0.4265) before stepwise removal.
Variables remaining significant after correction for multiple testing (P < 0.006) are shown in bold.
TABLE 3 | Validity of genotypes in predicting efavirenz plasma concentrations above 4µg/mL.
Risk factors for EFV plasma concentration > 4µg/mL Sensitivity (%) Specificity (%) Positive predictive Negative predictive
value (%) value (%)
CYP2B6 c.516T/T 47.8 93.5 76.7 79.9
CYP2B6 c.983C/C 7.2 100 100 70.0
CYP2B6 c.485-18C/C 97.1 14.7 35.1 91.3
CYP2B6 c.1421T/T 83.1 44.4 40.6 85.1
NR1I3 c.239-1089C/C 42.0 67.8 37.2 72.0
ABCB1 c.193G/G 4.3 97.4 42.9 69.3
CYP2B6 poor metabolizers (i.e., c.516T/T or c.983C/C or c.516G/T + c.983T/C) 68.1 93.4 82.5 86.5
CYP2B6 poor metabolizers together with CYP2B6 c.485-18C carriers 69.1 93.0 82.5 86.3
CYP2B6 poor metabolizers together with CYP2B6 c.1421T carriers 66.2 94.4 84.3 85.9
CYP2B6 poor metabolizers together with NR1I3 c.239-1089C carriers 58.0 97.3 90.9 83.2
CYP2B6 poor metabolizers together with ABCB1 c.193G carriers 17.4 97.4 75.0 72.1
and host genetic variation can influence the pharmacokinetic
variability of EFV (Burger et al., 2006; Rotger et al., 2006; Stohr
et al., 2008). Alcohol consumption and BMI were included in the
multivariate logistic regression analysis as potential contributors
to EFV plasma concentrations> 4µg/mL. However, themajority
of HIV/AIDS patients were females which might be the reason
for the very low smoking and alcohol consumption among
the patients. Smoking and alcohol consumption is generally
a less common lifestyle among female Bantu-speaking South
Africans, compared to other racial groups. In this study, EFV
plasma concentrations were higher in patients with a lower BMI
supporting observations by Poeta et al. (2011) and Stohr et al.
(2008).
Genetic variation in genes coding for DMEs responsible for
EFV metabolism is known to affect EFV plasma concentrations,
thus, a comprehensive analysis on the contribution of
genetic variants in genes coding for enzymes involved in
EFV metabolism was carried out. CYP2B6 c.516G>T and
c.983T>C SNPs are well-characterized predictors of EFV plasma
concentration (Haas et al., 2004; Swart et al., 2013) and here
we re-confirm their importance. Dhoro et al. (2015) reported
that Zimbabwean HIV/AIDS patients carrying the CYP2B6
c.516T/T genotype had 63% decreased EFV clearance. Mukonzo
et al. (2014) also reported an association of CYP2B6 c.516T/T
genotype with increased EFV exposure among Ugandan patients
leading to their recommendation of daily doses of 300mg for
CYP2B6 c.516T/T genotype carriers.
Five individuals with the CYP2B6 c.983C/C genotype were
identified in this study and four of these patients had nearly
five-fold higher EFV plasma concentrations (34.4, 21.8, 12.1,
and 22.3µg/mL) with respect to the therapeutic range upper
limit of 4µg/mL. CYP2B6 c.983C-allele has been associated
with significant differences in EFV exposure among individuals
of African and Caucasian ancestry (Gatanaga et al., 2007;
Wyen et al., 2008; Haas et al., 2009). Multivariate logistic
regression analysis showed an additive effect between the
CYP2B6 c.516G>T and c.983T>C SNPs with an almost two-
fold higher EFV plasma concentration, a finding in agreement
with reports by Wyen et al. (2008) and Schipani et al. (2011).
These observations suggest that CYP2B6 polymorphisms can
be used as biomarkers of EFV plasma concentration, further
arguing for genotype-assisted dosing with respect to the use
of EFV-containing HAART (Rotger et al., 2007; Rotger and
Telenti, 2008; Schipani et al., 2011). Recommendations based
on pharmacogenetics knowledge are being proposed, such as
gradual reductions in EFV dose from 600 to 400 or 200
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mg/day for intermediate metabolizer and poor metabolizer
patient groups, respectively (Gatanaga et al., 2007; Cabrera
et al., 2009; Mukonzo et al., 2014). The recently completed
ENCORE1 study (including 37% African individuals) concluded
that HIV suppression was comparable between EFV doses of 400
and 600mg daily (Dickinson et al., 2015). Bisaso et al. (2015)
suggested a 7% reduction in neuropsychological impairment
probability at an EFV dose of 450 mg/day. The cost-effectiveness
of using CYP2B6 genotyping to adjust EFV dosage was assessed
recently by Schackman et al. (2015). The cost-effectiveness
ratio of genotype-assisted dosing compared to a lower universal
dose remains greater than $ 100,000/quality-adjusted life years,
unless HIV RNA suppression is decreased by more than 15%
(Schackman et al., 2015).
In addition to univariate analysis, haplotypes were inferred for
each HIV/AIDS patient and median EFV plasma concentrations
were compared between haplotype groups. The effect of the
CYP2B6 c.516G>T SNP is shown by the significantly higher
median EFV plasma concentration for the CYP2B6 A-T-G-T-(C
or T)-C-G-(T or A)-G-AG-T haplotype compared to the A-G-A-
T-C-C-G-A-G-AG-T and A-G-A-T-C-C-G-A-G-CA-C haplotypes.
However, only four of the nine haplotypes with the CYP2B6
c.516T-allele, had median EFV plasma concentrations above
4µg/mL. This observation points to the potential involvement
of additional SNPs in CYP2B6 or other genes coding for DMEs
that play a role in EFV metabolism.
Furthermore, multivariate logistic regression analysis was
performed to identify additional contributors to variability in
EFV plasma concentration. Few studies have investigated the
effect of SNPs in the 3′-UTR of genes coding for DMEs in drug
response. A trend towards low EFV plasma concentration was
observed for the CYP2B6 c.1421C-allele which is located in the
3′-UTR. The CYP2B6 c.1421T>C SNP is predicted to affect the
binding of miR-3612, miR-650, miR-4266, miR-4779, miR-4695-
5p, miR-765, miR-4476, miR-6077, miR-6876-5p, and miR-8065
(Swart and Dandara, 2014) and, thus, potentially alter levels of
CYP2B6 mRNA.
In addition to CYP2B6 c.516G>T and c.983T>C SNPs,
the NR1I3 c.239-1089T>C, ABCB1 c.193A>G, CYP2B6 c.485-
18C>T, and CYP2B6 c.1421T>C SNPs potentially further
contribute to variability in EFV plasma concentration. However,
sensitivity, specificity, positive, and negative predictive values
for each SNP alone was low, but combining the CYP2B6
c.516G>T and c.983T>C SNPs improved the predictive values
further arguing for their utility in a pharmacogenetics-based test.
Further, addition of the CYP2B6 c.485-18C>T SNP improved
the sensitivity from 68 to 69%. Inclusion of the NR1I3 c.239-
1089T>C, ABCB1 c.193A>G, and CYP2B6 c.1421T>C SNPs did
not improve predictive ability of the CYP2B6 poor metabolizers
(PMs) genotyping test.
Comparison of Allele Frequencies
The current study shows major differences in variant allele
frequencies of SNPs between ethnic groups. Allele frequencies
were significantly different between African and other
populations especially for NR1I2 c.522C>T, NR1I2 c.1195A>C,
and NR1I2 c.1232T>C SNPs. NR1I2 codes for the nuclear
receptor PXR and is responsible for regulating most genes
coding for Phase I, Phase II enzymes, and transporters. PXR
is activated by many ligands including the antimalarial drug
artemisinin (Burk et al., 2005) and EFV (Healan-Greenberg
et al., 2008). Furthermore, it appears the UGT2B7 c.211G>T
SNP is specific to Asian populations, while NR1I2 c.659C>T
and c.838G>A SNPs are rare among Asians. Differences in
allele distribution are likely to contribute to the observed ethnic
variability in drug levels.
Inter-ethnic variations in drug exposure may possibly
result in varying clinical treatment outcome or adverse event
profiles between populations (Ngaimisi et al., 2013). African
populations are the most genetically diverse, thus, should
be utilized in clinical trials to enable the teasing out of
genetic correlates of drug response. The high prevalence of
HIV/AIDS in South Africa, combined with the exposure
to ARVs necessitates characterizing the genetic variation of
pharmacogenetically relevant genes to improve drug response
(Colic et al., 2015).
The current study is a continuation of earlier studies to assess
the contribution of 30 SNPs, especially those in the 3′-UTR of
genes that code for DMEs metabolizing EFV. The association or
trend toward low median EFV plasma concentration observed
for the NR1I3 c.239-1089T-allele, the ABCB1 c.193A-allele, the
CYP2B6 c.485-18T-allele, and the CYP2B6 c.1421C-allele need
to be investigated in further replication and larger cohorts.
Compared toCYP2B6 c.516G>T and c.983T>C SNPs, theNR1I3
c.239-1089T>C, ABCB1 c.193A>G, CYP2B6 c.485-18C>T, and
CYP2B6 c.1421T>C SNPs seem to play minor roles in predicting
EFV plasma concentrations above 4µg/mL.
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